C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 7/01 (2006.01) A61K 35/76 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C12N 15/11 (2006.01) C12N 15/86 (2006.01)
Patent
CA 2625811
The invention provides methods for preferentially killing target cells in a host by infecting the cells with one or more strains of a lytic virus that has been engineered to be susceptible to microRNA mediated translational repression. Methods of the invention thereby exploit differential microRNA expression in target and non- target cells of the host. For example, altered expression of microRNAs in cancer cells can be exploited to alter expression of a viral gene in cancer cells, compared to non0cancerous cells, to achieve tumour specific replication of an engineered virus, such as a vesicular stomatitis virus (VSV). In a selected embodiment, incorporation of let-7a microRNA complementary sequences within the VSV genome attenuates viral replication and associated toxicity in normal cells, but permits growth in cancer cells.
Bell John C.
Edge Robert
Ottawa Health Research Institute
Ottawa Hospital Research Institute
Smart & Biggar
LandOfFree
Microrna mediated oncolytic targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microrna mediated oncolytic targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microrna mediated oncolytic targeting will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1369770